CANbridge Pharmaceuticals Presents Positive Phase I Data for CAN106 at EHA Congress
China-based rare disease firm CANbridge Pharmaceuticals Inc. (HKG: 1228) released the latest data from a...
Clinical trial results
Ascentage Pharma’s Lisaftoclax Shows Promising Results in Phase I Trial for Non-Hodgkin Lymphoma
Suzhou-based Ascentage Pharma (HKG: 6855) announced the publication of Phase I clinical study results for...
Ascentage Pharma’s Lisaftoclax Shows Promising Results in Phase I Trial for Non-Hodgkin Lymphoma
Suzhou-based Ascentage Pharma (HKG: 6855) announced the publication of Phase I clinical study results for...
Genscript’s CAR-T Therapy JNJ-4528 Demonstrates 100% Effective Rate in Long-Term Myeloma Study
Genscript Biotech Corporation (HKG: 1548), a leading China-based Contract Development and Manufacturing Organization (CDMO), has...
Innovent Biologics and Eli Lilly & Co.’s Tyvyt Achieves Primary Endpoints in Phase II ESCC Clinical Study
Innovent Biologics (HKG: 1801), a prominent biotech firm headquartered in Suzhou, China, and Eli Lilly...